CU20230026A7 - Formas cristalinas de inhibidor de integrina y sales de estas - Google Patents
Formas cristalinas de inhibidor de integrina y sales de estasInfo
- Publication number
- CU20230026A7 CU20230026A7 CU2023000026A CU20230026A CU20230026A7 CU 20230026 A7 CU20230026 A7 CU 20230026A7 CU 2023000026 A CU2023000026 A CU 2023000026A CU 20230026 A CU20230026 A CU 20230026A CU 20230026 A7 CU20230026 A7 CU 20230026A7
- Authority
- CU
- Cuba
- Prior art keywords
- crystalline forms
- salts
- integrin inhibitor
- methods
- inhibitors
- Prior art date
Links
- 229940125798 integrin inhibitor Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002411 thermogravimetry Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente descripción se proporcionan inhibidores de integrina, composiciones de estos, y métodos para su uso. También se describen formas cristalinas de sales de los inhibidores, junto con métodos para preparar las formas cristalinas. Se proporcionan datos de difracción de polvo de rayos X, análisis termogravimétrico, y datos de calorimetría diferencial de barrido de las formas cristalinas. Los inhibidores de integrina son útiles en el tratamiento de, entre otras, las enfermedades fibróticas.</p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063116042P | 2020-11-19 | 2020-11-19 | |
PCT/US2021/072510 WO2022109598A1 (en) | 2020-11-19 | 2021-11-19 | Integrin inhibitor and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20230026A7 true CU20230026A7 (es) | 2024-01-10 |
Family
ID=81709878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2023000026A CU20230026A7 (es) | 2020-11-19 | 2021-11-19 | Formas cristalinas de inhibidor de integrina y sales de estas |
Country Status (18)
Country | Link |
---|---|
US (1) | US12018025B2 (es) |
EP (1) | EP4247472A1 (es) |
JP (1) | JP2023550428A (es) |
KR (1) | KR20230121761A (es) |
CN (1) | CN116710169A (es) |
AU (1) | AU2021381516A1 (es) |
CA (1) | CA3173755A1 (es) |
CL (1) | CL2023001418A1 (es) |
CO (1) | CO2023006522A2 (es) |
CR (1) | CR20230262A (es) |
CU (1) | CU20230026A7 (es) |
DO (1) | DOP2023000101A (es) |
EC (1) | ECSP23045278A (es) |
IL (1) | IL302651A (es) |
MX (1) | MX2023005889A (es) |
PE (1) | PE20240114A1 (es) |
TW (1) | TW202235417A (es) |
WO (1) | WO2022109598A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
IL279717B2 (en) | 2018-06-27 | 2024-05-01 | Pliant Therapeutics Inc | Amino acid compounds with non-branched linkers and methods of use |
TW202408530A (zh) * | 2022-07-09 | 2024-03-01 | 美商普萊恩醫療公司 | 整合素抑制劑及其與其他藥劑併用之用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
JP2018515424A (ja) | 2015-03-10 | 2018-06-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗アルファvベータ1インテグリン阻害剤及び使用方法 |
EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING |
EP3558303A4 (en) | 2016-12-23 | 2020-07-29 | Pliant Therapeutics, Inc. | AMINO ACID COMPOUNDS AND METHOD FOR USE |
MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
RU2769702C2 (ru) | 2017-02-28 | 2022-04-05 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
BR112020018064A2 (pt) | 2018-03-07 | 2020-12-22 | Pliant Therapeutics, Inc. | Compostos de aminoácidos e métodos de uso |
IL279717B2 (en) | 2018-06-27 | 2024-05-01 | Pliant Therapeutics Inc | Amino acid compounds with non-branched linkers and methods of use |
JP7314135B2 (ja) * | 2018-07-20 | 2023-07-25 | 株式会社半導体エネルギー研究所 | 撮像装置 |
EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INTEGRIN (ALPHA-V)(BETA-6) INHIBITORS |
EP3843728A4 (en) | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
JP2022523621A (ja) * | 2018-12-28 | 2022-04-26 | ルナピービーシー | コミュニティデータの集約、完成、修正、および使用 |
US11730144B2 (en) * | 2019-02-15 | 2023-08-22 | Clean Bite, Llc | Oral hygiene appliance |
SG11202110889WA (en) * | 2019-04-08 | 2021-10-28 | Pliant Therapeutics Inc | Dosage forms and regimens for amino acid compounds |
MX2022005904A (es) | 2019-11-15 | 2022-09-07 | Pliant Therapeutics Inc | Composiciones y metodos para la activacion de integrinas. |
MX2022013753A (es) * | 2020-05-07 | 2023-01-30 | Pliant Therapeutics Inc | Tratamiento de enfermedades respiratorias con compuestos de aminoacidos. |
IL298082A (en) * | 2020-06-03 | 2023-01-01 | Gilead Sciences Inc | lpa receptor antagonists and uses thereof |
TW202233224A (zh) * | 2020-10-21 | 2022-09-01 | 美商寇峇有限公司 | 用組合療法治療纖維化之方法 |
TW202308637A (zh) | 2021-04-30 | 2023-03-01 | 美商普萊恩醫療公司 | 整合素抑制劑之擴大劑量方案 |
CA3173754A1 (en) | 2021-09-03 | 2024-03-02 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
IL312083A (en) | 2021-10-14 | 2024-06-01 | Pliant Therapeutics Inc | Integrin inhibitors and their uses in combination with other substances |
WO2023225119A1 (en) | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
-
2021
- 2021-11-19 AU AU2021381516A patent/AU2021381516A1/en active Pending
- 2021-11-19 WO PCT/US2021/072510 patent/WO2022109598A1/en active Application Filing
- 2021-11-19 PE PE2023001662A patent/PE20240114A1/es unknown
- 2021-11-19 JP JP2023530225A patent/JP2023550428A/ja active Pending
- 2021-11-19 CU CU2023000026A patent/CU20230026A7/es unknown
- 2021-11-19 CN CN202180090550.5A patent/CN116710169A/zh active Pending
- 2021-11-19 EP EP21895890.8A patent/EP4247472A1/en active Pending
- 2021-11-19 US US17/531,074 patent/US12018025B2/en active Active
- 2021-11-19 CA CA3173755A patent/CA3173755A1/en active Pending
- 2021-11-19 TW TW110143265A patent/TW202235417A/zh unknown
- 2021-11-19 CR CR20230262A patent/CR20230262A/es unknown
- 2021-11-19 MX MX2023005889A patent/MX2023005889A/es unknown
- 2021-11-19 KR KR1020237020570A patent/KR20230121761A/ko unknown
- 2021-11-19 IL IL302651A patent/IL302651A/en unknown
-
2023
- 2023-05-17 CL CL2023001418A patent/CL2023001418A1/es unknown
- 2023-05-17 CO CONC2023/0006522A patent/CO2023006522A2/es unknown
- 2023-05-18 DO DO2023000101A patent/DOP2023000101A/es unknown
- 2023-06-16 EC ECSENADI202345278A patent/ECSP23045278A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MX2023005889A (es) | 2023-06-06 |
EP4247472A1 (en) | 2023-09-27 |
IL302651A (en) | 2023-07-01 |
AU2021381516A1 (en) | 2023-06-22 |
WO2022109598A1 (en) | 2022-05-27 |
CA3173755A1 (en) | 2022-05-27 |
CO2023006522A2 (es) | 2023-06-09 |
PE20240114A1 (es) | 2024-01-22 |
JP2023550428A (ja) | 2023-12-01 |
TW202235417A (zh) | 2022-09-16 |
US12018025B2 (en) | 2024-06-25 |
CN116710169A (zh) | 2023-09-05 |
ECSP23045278A (es) | 2023-07-31 |
KR20230121761A (ko) | 2023-08-21 |
DOP2023000101A (es) | 2023-09-29 |
US20220177468A1 (en) | 2022-06-09 |
CL2023001418A1 (es) | 2023-10-30 |
CR20230262A (es) | 2023-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20230026A7 (es) | Formas cristalinas de inhibidor de integrina y sales de estas | |
CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
ECSP22046699A (es) | Inhibidores de kras g12c | |
ECSP109910A (es) | Derivados de n-(arilamino) sulfonamidas que incluyen polimorfos como inhibidores de mek así como composiciones, métodos de uso y de preparación de los mismos | |
CY1124206T1 (el) | Αναστολεις πυριδοπυριμδινονης cdk2/4/6 | |
UY38553A (es) | Inhibidores de cdk2 | |
CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
UY38752A (es) | Derivados de benzisoxazol sulfonamida | |
CY1109072T1 (el) | Βητα κρυσταλλικη μορφη του υδροχλωρικου αλατος της ιβαμπραδινης, μεθοδος παρασκευης αυτου και φαρμακευτικης συνθεσεις που το περιεχουν | |
CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas | |
UY38471A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
CY1126141T1 (el) | Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπης | |
ECSP16074478A (es) | Compuestos novedosos | |
UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
UY39517A (es) | Inhibidores de la btk | |
AR083268A1 (es) | Conjugado de naloxol-peg cristalino | |
CO2021010930A2 (es) | Hidroxipiridoxazepinas como activadores de nrf2 | |
UY35536A (es) | ?derivados de sulfonamida?. | |
CO2022015157A2 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
CR20190344A (es) | Activador de nrf2 | |
UY36546A (es) | “ciclopropabenzofuranil-piridopirazindionas novedosas”. | |
AR061299A1 (es) | Sales de succionato de 6-metoxi -8- [4- (1-(5- fluor) -quinolin -8-il-piperidin-4-il) -piperazin-1-il] -quinolina y formas cristalinas de las mismas | |
CO2018007610A2 (es) | Derivados de indano y su uso en terapias | |
CL2019001008A1 (es) | Formas cristalinas de 4–(2–((1r,2r)–2–hidroxiciclohexilamino) benzotiazol–6–iloxi)–n–metilpicolinamida. |